Lutetium Lu-177 PNT2002
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oligometastatic Prostate Carcinoma
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Trial Timeline
Sep 2, 2022 → Sep 1, 2033
NCT ID
NCT05496959About Lutetium Lu-177 PNT2002
Lutetium Lu-177 PNT2002 is a phase 2 stage product being developed by Eli Lilly for Oligometastatic Prostate Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05496959. Target conditions include Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Oligometastatic Prostate Carcinoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05496959 | Phase 2 | Active |
Competing Products
5 competing products in Oligometastatic Prostate Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab | Merck | Phase 2 | 42 |
| Pembrolizumab | Merck | Phase 3 | 47 |
| AAA617 | Novartis | Phase 3 | 47 |
| Actinium Ac 225 Vipivotide Tetraxetan + Lutetium Lu 177 Vipivotide Tetraxetan | Novartis | Phase 2 | 42 |
| Quemliclustat + Etrumadenant + Zimberelimab | Arcus Biosciences | Phase 2 | 36 |